Prevalence,clinical features and treatment of depression in Parkinson’s disease:An update

Omar ME Abdel-Salam

文献导航

搜索文章

搜索思路

钛学术文献服务平台 \
学术期刊 \
医药卫生期刊 \
神经病学与精神病学期刊 \
世界神经病学杂志期刊 \
Prevalence,clinical features and treatment of depression in Parkinson’s disease:An update

Prevalence,clinical features and treatment of depression in Parkinson’s disease:An update

作者：

Omar ME Abdel-Salam

基本信息来源于合作网站，原文需代理用户跳转至来源网站获取

ANTIDEPRESSANT

drugs

DEPRESSION

SEROTONIN

REUPTAKE

inhibitors

Parkinson’s

disease

TRICYCLIC

antidepressants

摘要：

Parkinson’s disease(PD)is one of the most prevalent neurodegenerative diseases which typically affects individuals over 65 years.Although the symptomatology is predominantly motor,neuropsychiatric manifestations,e.g.,depression,apathy,anxiety,and cognitive impairment occur in the course of the illness and can have a great impact on the quality of life in these patients.Parkinson’s disease is commonly comorbid with depression with prevalence rates of depression,generally higher than those reported in general population.Depression in PD is frequently underestimated and consequently undertreated,which have significant effects on the quality of life in these patients.The neurobiology of depression in PD is complex and involves alterations in dopaminergic,serotonergic,noradrenergic and possibly other neurotransmitter systems which are affected in the course of the disease.The tricyclic antidepressants and the selective serotonin reuptake inhibitors are the two classes of antidepressant drugs used for depressive symptoms in PD.Several published studies suggested that both classes are of comparable efficacy.Other serotonergic antidepressants,e.g.,nefazodone and trazodone have also been of benefit.Meanwhile,there are limited data available on other drugs but these suggest a benefit from the serotonin and noradrenaline reuptake inhibitors such as mirtazapine,venlafaxine,atomoxetine and duloxetine.Some of the drugs used in symptomatic treatment of PD,e.g.,the irreversible selective inhibitors of the enzyme monoamine oxidase-B,rasagiline and selegiline as well as the dopamine receptor agonist pramipexole are likely to have direct antidepressant activity independent of their motor improving action.This would make these drugs an attractive option in depressed subjects with PD.The aim of this review is to provide an updated data on the prevalence,clinical features of depression in subjects with PD.The effects of antiparkinsonian and antidepressant drugs on depressive symptoms in these patients are also discussed.

内容分析

关键词云

关键词热度

相关文献

推荐文献

根据相关规定，获取原文需跳转至原文服务方进行注册认证身份信息

完成下面三个步骤操作后即可获取文献，阅读后请点击下方页面【继续获取】按钮

钛学术文献服务平台

学术出版新技术应用与公共服务实验室出品

原文合作方

获取文献流程

1.访问原文合作方请等待几秒系统会自动跳转至登录页，首次访问请先注册账号，填写基本信息后，点击【注册】

2.注册后进行实名认证，实名认证成功后点击【返回】

3.检查邮箱地址是否正确，若错误或未填写请填写正确邮箱地址，点击【确认支付】完成获取，文献将在1小时内发送至您的邮箱

*若已注册过原文合作方账号的用户，可跳过上述操作，直接登录后获取原文即可

点击【获取原文】按钮，跳转至合作网站。

首次获取需要在合作网站进行注册。

注册并实名认证，认证后点击【返回】按钮。

确认邮箱信息，点击【确认支付】，订单将在一小时内发送至您的邮箱。

* 若已经注册过合作网站账号，请忽略第二、三步，直接登录即可。

期刊分类
期刊（年）
期刊（期）
期刊推荐

中国医学临床医学五官科学内科学医疗保健医药卫生总论基础医学外科学大学学报妇产科学与儿科学特种医学皮肤病学与性病学神经病学与精神病学肿瘤学药学预防医学与卫生学

世界神经病学杂志2017 世界神经病学杂志2016 世界神经病学杂志2015 世界神经病学杂志2014 世界神经病学杂志2013 世界神经病学杂志2012 世界神经病学杂志2011

世界神经病学杂志2015年第4期世界神经病学杂志2015年第3期世界神经病学杂志2015年第2期世界神经病学杂志2015年第1期

按字母查找期刊：

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
其他

联系合作广告推广: shenyukuan@paperpass.com

篇名	Prevalence,clinical features and treatment of depression in Parkinson’s disease:An update
来源期刊	世界神经病学杂志	学科	医学
关键词	ANTIDEPRESSANT drugs DEPRESSION SEROTONIN REUPTAKE inhibitors Parkinson’s disease TRICYCLIC antidepressants
年，卷（期）	2015,（1）	所属期刊栏目
研究方向		页码范围	17-38
页数	22页	分类号	R743.3
字数		语种
DOI